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Background: This descriptive study was conducted to examine the changes in the symptom frequency in patients
with rapid eye movement (REM) sleep behavior disorder (RBD) without medical intervention, in order to determine
the association of RBD symptom frequency with disease duration.
Methods: Data were collected from 70 consecutive RBD patients who visited the Sleep Clinic in Shiga University of
Medical Science. RBD symptom frequencies at the first visit to the clinic were quantified based on the reports by
the patients and their family members. For quality assurance, patients living alone or those with cognitive decline
were excluded. Finally, 50 patients with family-confirmed symptom history were enrolled. The symptom frequencies
were converted to a unit that reflects the estimated number of nights in a year affected by RBD (NAR). Using NAR,
we observed the relation between RBD symptom frequency and the disease duration.
Results: Of the 50 patients, 41 were male and 9 were female, consistent with the male-dominant nature of this disease.
The mean age at RBD onset was 62.2 ± 9.1 years, and the mean disease duration at the time of visit was 6.0 ± 4.9 years.
The median symptom frequency was 50 NAR, with a 1st quantile value of 24 NAR and a 3rd quantile value of 115 NAR.
When RBD symptom frequency was plotted against disease duration, we found that the frequency was lowest in the first
2 years of RBD (median, 18; range, 2–29 NAR), and higher frequencies were found in 2-year bin groups from 2 to 8 years
after RBD onset (median, 60; range, 50–150 NAR). Intriguingly, after 8 years of RBD, the frequency returned to a level
comparable to that in the first 2 years of RBD (median, 50; range, 12–100 NAR).
Conclusions: There was no association between RBD symptom frequency and disease duration. RBD clinical symptoms
could be less prominent when neural damage becomes severe. Therefore, a natural decrease in RBD symptom frequency
may be indicative of progression of neurodegeneration.
Keywords: REM Sleep Behavior Disorder, Symptom frequency, Disease durationBackground
Rapid eye movement (REM) sleep behavior disorder
(RBD) is a sleep-related disorder characterized by
vocalization and violent enactment during REM sleep.
Recently, this type of parasomnia has drawn attention
because RBD is believed to share a common neuropath-
ology with alpha-synucleinopathies, including Parkin-
son’s disease (PD), dementia with Lewy bodies (DLB),* Correspondence: masahiro.matsuo@gmail.com
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Gilman et al. 2008). Intriguingly, RBD symptoms typic-
ally appear before the onset of PD, DLB and MSA. Al-
though the occurrence rates vary among reports, a
recent study found that PD or DLB occurred in about
81% of RBD patients at a mean of 14.2 years after RBD
onset (Schenck et al. 2013a).
Based on these findings, much effort has been put into
assessing whether RBD could be used as a predictor of
severe symptoms, such as deteriorated motor function
and cognitive decline (Fujishiro et al. 2013). Recently,
detection of preclinical phase of Alzheimer’s disease isle is distributed under the terms of the Creative Commons Attribution 4.0
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burden. For example, an early intervention that extends
well-being by 5 years is estimated to reduce the cost re-
lated to the disease by 50% (Sperling et al. 2011). Like-
wise, identifying the preclinical phase of PD/DLB/MSA
may lead to significant reduction of the medical cost.
Thus, an appropriate approach to assess precursor
symptoms is essential to reduce social burden and im-
prove patient quality of life.
Although RBD has been shown to be a prodromal
symptom of PD/DLB/MSA (Mahowald & Schenck 2013),
the method to quantify or assess RBD symptom severity
has not been well studied. This is typically problematic in
PD/DLB/MSA because the time relationship between
RBD onset and PD/DLB/MSA onset varies considerably
(Schenck et al. 2013a; Fujishiro et al. 2013). It is often clin-
ically experienced that RBD symptoms disappear over the
course of PD/DLB/MSA progression. In a study targeting
early PD patients, it was reported that 15% of the subjects
without concurrent RBD symptoms reported cessation of
RBD symptoms prior to the study (Bugalho et al. 2011).
Similar findings were reported for MSA, where 50% of the
MSA patients with RBD symptoms reported disappear-
ance of these symptoms (Nomura et al. 2011).
In order to determine the association of RBD symptom
frequency with RBD duration, we semi-quantitatively ex-
amined RBD symptoms based on the frequency of dream-
related enactments or vocalizations, and, using this
method, we retrospectively examined the RBD symptom
frequency at the time of clinic visit when no medical ac-
tion was taken.
Materials and Methods
Participants
We retrospectively collected the medical records of RBD
patients who visited Shiga University of Medical Science
between June 1, 2008 and December 31, 2015. Patients
who satisfied following inclusion criteria were included in
this study: (a) having a diagnosis of RBD based on the 2nd
edition of the International Classification of Sleep Disor-
ders (ICSD-2) criteria, and (b) being able to report the on-
set time as well as frequency of RBD symptoms, which
were consistent with those reported by their families. Be-
cause reporting of RBD symptom frequency was pivotal in
this study, patients meeting the criteria for dementia, as
defined in DSM-IV-TR, were excluded. Also, subjects
were investigated for whether they satisfied the diagnostic
criteria for PD (Hughes et al. 1992), DLB (McKeith et al.
2005), and MSA (Gilman et al. 2008). Patients who ful-
filled all criteria for RBD were diagnosed as having definite
RBD, and those who were not confirmed with RBD on
video-polysomnography examination were diagnosed as
having probable RBD (Boeve et al. 2007). All diagnoses
were independently reviewed and confirmed by two trainedphysicians (YS and MM). RBD symptoms were confirmed
using video recordings and concurrent respiratory monitor
recordings to differentiate them from activities related to
sleep apnea that has been reported to have symptoms re-
sembling RBD symptoms (Iranzo & Santamaria 2005). All
subjects were inquired about the current intake of antide-
pressants as they are known to cause RBD.
Symptom frequency
Patients were asked about the approximate year and
month of RBD onset. Symptom frequencies were quanti-
fied as the approximate number of nights per year in
which RBD symptoms were estimated to have occurred.
Conventionally, we defined this frequency unit as Nights
affected by RBD (NAR). For example, when a patient re-
ported that symptoms appeared every night, the fre-
quency was quantified as 365 NAR. If a patient reported
a range, such as 2–3 nights per week, the estimation was
based on the greater number in the report, and thus, the
frequency was quantified as 150 NAR (calculated as fol-
lows: 3/7 × 365 ≒ 150). Although all symptom frequen-
cies were reported by patients and confirmed by their
family members, onset time was rated as unknown when
both family members and the patient reported that the
time of RBD onset was unclear.
Statistical analysis
Data are presented as mean ± standard deviation, unless
otherwise stated. The Student’s t-test was used to statis-
tically compare the 2 groups. For statistical comparisons
of symptom frequencies at different time points, the
Kruskal-Wallis test was used, followed by Dunn’s mul-
tiple comparison test. The differences in the occurrence
of definite RBD and probable RBD between females and
males were examined using χ2 test.
Multivariate logistic regression analysis was performed
to estimate the association between disease features and
RBD symptom frequency. Odds ratios (ORs) and 95%
confidence intervals (95% CIs) were calculated after con-
trolling simultaneously for potential confounders. The ex-
planatory variables included sex, BMI, RBD onset age, and
duration of RBD. Statistical analyses were performed using
IBM SPSS Statistics for Macintosh, Version 22.0(IBM
Corp. Armonk, NY).
Ethical consideration
The study protocol was approved by the ethics commit-
tee of Shiga University of Medical Science (27–229). In-
formed consent was obtained by the use of an opt-out
methodology, owing to the low risk nature of this study.
Results
We collected RBD data between June 1, 2008 and
December 31, 2015. During this period, 70 patients had
Fig. 1 RBD symptom frequency at sleep clinic visit. A histogram
representation of the RBD symptom frequency distribution. The
x-axis shows the RBD symptom frequency in NAR units. The y-axis
shows the number of patients in every 20 NAR bin group
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fined elsewhere (Boeve et al. 2007). Among these patients,
1 was excluded because of comorbid Alzheimer’s dementia.
Additionally, 17 patients were excluded because of inad-
equate validity of information on symptom frequency, and
2 were excluded because RBD onset was unclear. All sub-
jects did not meet the diagnostic criteria for PD, DLB, or
MSA. Therefore, 50 patients were finally included in this
study (Table 1). The patients were predominantly male,
reflecting the male-dominant nature of this disease
(Postuma et al. 2016). The mean age at RBD onset was
62.2 ± 9.1 years, and there was no significant difference in
the age at onset between female and male patients (57.5 ±
15.1 vs. 63.2 ± 6.7, respectively, two-tailed t-test p > 0.05).
Also, there were no sex-related differences in BMI and dis-
ease durations (two-tailed t-test, p > 0.05) in our study sam-
ple. There was no significant difference in the proportions
of definite or probable RBD between females and males (χ2
test, p > 0.05). Nineteen subjects had sleep apnea syndrome
as their apnea–hypopnea index (AHI) value was greater
than 5, which was confirmed by video PSG.
Of the 50 study patients, 31 were diagnosed with definite
RBD and 19 with probable RBD. There were no significant
differences in the RBD onset age or duration of symptoms
between the 2 groups of patients (data not shown).
On assessing the distribution of symptom frequencies at
the first visit to our sleep clinic, we noted a skewed distri-
bution. Many patients reported rare occurrences of symp-
toms, and the numbers of patients decreased as the RBD
symptom frequency increased (Fig. 1). In this analysis,
60% of the patients reported that symptoms appeared no
more than once per a week (50 NAR). In contrast, 4 pa-
tients reported that RBD symptoms appeared every day,
and this group represented a small peak at 365 NAR. The
median symptom frequency was 50 NAR, with a 1st quan-
tile value of 24 NAR and a 3rd quantile value of 115 NAR.
In addition to the symptom frequency profile, we exam-
ined the changes in the symptom frequency during the
time course after RBD onset. We found that the RBD
symptom frequency did not continuously increase as a
function of the disease duration and that RBD symptoms
appeared most frequently in the second 5-year period of
the disease (Fig. 2). To confirm the differential symptom
frequency after disease onset, we performed statistical ana-
lysis by binning every 2 years of disease duration. WeTable 1 Demographic data of the participants
All Male Female p
N 50 41 9
BMI 22.4 ± 3.20 22.7 ± 3.09 21.0 ± 3.33 0.608
Age at RBD onset 62.2 ± 9.13 63.2 ± 6.67 57.5 ± 15.1 0.320
RBD duration 6.0 ± 4.9 6.5 ± 5.0 3.9 ± 3.7 0.587
Definite/Probable RBD 31/19 24/17 7/2 0.282combined patients with a disease history of more than
8 years into one group, because of the small number of pa-
tients in this group. The analysis showed that RBD symp-
toms appeared approximately 1–2 times a month in the
first 2 years of RBD (median, 18 NAR; range, 2–29 NAR;
Table 2 and Additional file 1: Figure S1). The symptomFig. 2 RBD frequencies and the relation with the RBD duration. A scatter
plot of RBD frequencies is shown. The x-axis denotes the duration of RBD
in years. The y-axis denotes the frequency of RBD symptoms in NAR units.
The blue spots represent RBD duration and RBD symptom frequency at
the first visit to our sleep clinic. For better understanding of the RBD
symptom frequency changes, trend is indicated with a red line, which
was generated using the locally weighted scatterplot smoothing method
Table 2 RBD symptom frequencies in every 2-year bin of RBD
duration
Symptom frequency (NAR)
Duration (years) n Median Interquartile range p
0–2 12 18 2–29 Reference
2–4 8 75 50–158 0.006
4–6 13 50 36–150 0.016
6–8 4 175 125–241 0.003
>8 13 50 12–100 0.280
All 50 50 24–115
NAR: Nights affected by RBD
The median RBD frequencies are calculated within each disease
duration group
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6 years, with median frequencies of 75 NAR for 2–4 years,
50 NAR for 4–6 years, and 175 NAR for 6–8 years. Inter-
estingly, 8 years after RBD onset, the frequency was com-
parable to that in the first 2 years (median, 50 NAR; range,
12–100 NAR). On the other hand, multiple comparison
test showed no significant differences among groups of 2–4
years, 4–6 years, 6–8 years, and over 8 years. Although a
report showed that patients with severe sleep apnea (AHI
around 60) can mimic RBD symptoms (Iranzo &
Santamaria 2005), NARs for 2–4 years and 4–6 year
groups remained significantly higher even after limiting
study subjects to patients with normal or mild apnea
(AHI less than 15, Additional file 2: Table S1). Also, the
main findings remained the same after excluding the patients
with antidepressant medication (Additional file 3: Table S2).
As the disease duration did not appear to be associated
with RBD symptom frequency, we assessed the possible as-
sociations between symptom frequency and other features
of the patients. For this assessment, we conducted multi-
variate analysis after controlling for possible cofounders, in-
cluding sex, BMI, and age at RBD onset. We found that
symptom frequency was not associated with sex, BMI, age
at RBD onset, or RBD duration (Table 3).
Discussion
Although RBD is known to be a prodromal symptom of
PD/DLB/MSA (Mahowald & Schenck 2013), the time-
dependent changes in RBD symptoms before PD/DLB/
MSA have not been well studied. In the present study,
we did not find any association between RBD symptom
frequency and disease duration.
Our finding that RBD symptoms were most frequent in
the 2–8 years of disease duration was unexpected. This
trend was statistically confirmed as NARs during 2–8
years of disease were comparable and remained constantly
higher than those during first 2 years, despite apparent
fluctuation in their median values. This trend could not be
explained by possible effects of antidepressants becausethe findings remained the same even after excluding three
subjects who were taking antidepressants. Also, SAS was
not likely the explanation for the current findings, because
NAR was significantly higher for groups with 2–4 and 4–
6 years of disease history than for those with 0–2 years
history after excluding moderate and severe SAS patients.
Poor statistical power could explain the reason why we
could not find significantly higher NAR in 6–8 years bin,
as exclusion of those SAS patients reduced the number of
study patients within this group.
Recent studies have shown that RBD is one of the mani-
festations of alpha-synucleinopathies (Boeve 2013), which
irreversibly damage the neural system (Boeve et al. 2007).
Consistent with this irreversible neural damage model, pre-
vious reports showed that the severity of REM atonia loss is
enhanced as the disease duration increases (Iranzo et al.
2009; Postuma et al. 2010). One explanation for the dis-
crepancy is that RBD symptom frequency could be discord-
ant with the severity of REM atonia loss. To conclude this
assumption, a future prospective study with follow-up PSG
will be required. However, current findings could be advan-
tageous for clinicians, as we focused on clinically observable
RBD symptom frequencies instead of muscle atonia, which
can only be observed with polysomnography examination.
Notably, some studies have reported a possibility that rate
of development of neurodegenerative disease is slower in
Asian RBD patients (Inoue 2016; Postuma 2013) than in
Caucasians. Along with the known heterogeneity of alpha-
synucleinopathies (Thenganatt & Jankovic 2014) and re-
ported ethnic differences in RBD rate, genetic background
of the patients could interfere with the progression rate and
frequency of appearance of RBD symptoms. Thus, current
findings could only reflect the characteristics limited to
Asian patients.
The present study has several limitations. First, our
study depended on the reports of patients and their
family members, and thus, there might have been recall
bias. The recall bias may apply to the accuracy of dis-
ease duration, as patients were often unsure of the
exact month of disease onset. Even with time resolution
of this level, current conclusion will not be affected
enormously because we conducted disease-duration–
related analysis on a 2-year bin basis. Another limita-
tion to our study is the exclusion of dementia patients.
This exclusion could result in a selection bias, in which
we observed the RBD population who does not proceed
to dementia. However, based on the reported high rates
and several years required to convert to dementia from
RBD, we believe the effect of this selection bias to be
minimal. Instead, the reliability of disease durations
was ensured by excluding dementia patients as well as
by confirmation from the family members. There may
have been another selection bias because only patients
visiting our sleep clinic were enrolled.
Table 3 Association between patient features and RBD symptom frequencies
Unadjusted Multivariable Adjusted (b)
OR (95% CI) p-value OR (95% CI) p-value
Sex −3.144 (−70.43 to 64.14) 0.926 −7.894 (−86.81 to 71.022) 0.841
BMI −0.913 (−8.990 to 7.163) 0.821 −1.113 (−9.663 to 7.436) 0.794
Onset age (years) −0.254 (−3.100 to 2.592) 0.858 −0.406 (−4.070 to 3.258) 0.824
Duration (years) 0.215 (−5.040 to 5.470) 0.935 −0.231 (−6.904 to 6.441) 0.945
Summary of the multivariate analysis results is presented. Odd ratios (ORs) and 95% confidence intervals (CIs) are shown for each explanatory variable
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spective nature of our study. This design was se-
lected to better follow the naturalistic evolution of
RBD. One factor that could hamper the observation
of the naturalistic evolution of RBD symptoms is the
fact that the symptoms could be resolved with medi-
cation (Schenck et al. 2013b; Li et al. 2016). Because
of this favorable action of medication, it is often dif-
ficult to observe the natural progression of symptom
change. Because of the same reason, the setting of
placebo cohort for comparison is not ethically allow-
able. Another factor is the long-lasting nature of
RBD symptoms, which require a long observation
duration. Indeed, Schenck et al. reported that RBD
onset occurs long before the onset of PD or DLB,
with a mean interval of 14.2 years and a wide range
of 5–29 years (Schenck et al. 2013a). This long and
varying duration is problematic for long-term obser-
vation and the eventual estimation of PD and DLB
occurrence. The current study circumvented these
obstructions by employing a retrospective review of
RBD symptom frequencies before medical interven-
tion. Using this strategy, we could observe the natur-
alistic evolution of RBD symptoms, which were not
quantitatively reported in the previous studies. This
observation shed new light on understanding the na-
ture of RBD progression and the possible link to
alpha-synucleinopathy occurrence.
Future studies will be required to develop precise
techniques that can assess RBD symptom progression
not only quantitatively but also qualitatively. Add-
itionally, longitudinal follow-up studies are required
to assess the relationship of RBD progression with
PD, DLB or MSA onset.Conclusion
There was no association between RBD symptom
frequency and disease duration. RBD clinical symp-
toms could be less prominent when neural damage
becomes severe. Therefore, decrease in RBD symp-
tom frequency may be indicative of progression of
neurodegeneration.Additional files
Additional file 1: Figure S1. Distributions of RBD frequencies within
each disease history bin. Distributions of RBD symptom frequency are
shown for every disease duration bin. The x-axis denotes the RBD
duration bin. The y-axis denotes the frequency of RBD symptoms in NAR
units. Median and interquartile range are shown. (PDF 339 kb)
Additional file 2: Table S1. RBD symptom frequencies in every 2-year
bin of RBD duration after excluding moderate and severe SAS patients.
(PDF 118 kb)
Additional file 3: Table S2. RBD symptom frequencies in every 2-year
bin of RBD duration after excluding patients on antidepressant medication.
(PDF 192 kb)
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